ALKS · Company research
Alkermes Inc. plc (ALKS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
23records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? | Harmony Biosciences (HRMY) has outperformed the market with a 27.6% share surge over six months, driven by robust Wakix sales growth of 24% to $476.7 million in H1 2026 and promising pipeline candidates BP-205 and EPX-100. The company maintains its $1.0-$1.04B full-year revenue guidance and has $962.5M in cash to fund development. However, competition from Jazz Pharmaceuticals' Xywav and Alkermes' Lumryz, along with patent litigation risks, present headwinds. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.333 | 1 |
| HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? | Harmony Biosciences (HRMY) has outperformed the market with a 27.6% share surge over six months, driven by robust Wakix sales growth of 24% to $476.7 million in H1 2026 and promising pipeline candidates BP-205 and EPX-100. The company maintains its $1.0-$1.04B full-year revenue guidance and has $962.5M in cash to fund development. However, competition from Jazz Pharmaceuticals' Xywav and Alkermes' Lumryz, along with patent litigation risks, present headwinds. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.333 | 1 |
| Sleep Data Might Change The Case For Investing In Alkermes Stock (ALKS) - Simply Wall Street | Sleep Data Might Change The Case For Investing In Alkermes Stock (ALKS) Simply Wall Street | View source ↗ | Simply Wall Street | Oct 14, 2026 | neutral | 0 | 0.6 |
| Eight sleep research presentations are planned, including detailed results from a LUMRYZ trial. - Stock Titan | Eight sleep research presentations are planned, including detailed results from a LUMRYZ trial. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| 4 CNS Drug Stocks Worth Watching This World Mental Health Day | Four central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| 4 CNS Drug Stocks Worth Watching This World Mental Health Day | Four central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Alkermes PLC (ALKS) Stock Down 3.2% but Still Overvalued -- GF S - GuruFocus | Alkermes PLC (ALKS) Stock Down 3.2% but Still Overvalued -- GF S GuruFocus | View source ↗ | GuruFocus | Oct 8, 2026 | neutral | 0 | 0.6 |
| Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo! Finance Canada | Alkermes plc (ALKS) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 6, 2026 | neutral | 0 | 0.6 |
| A 2,034-share sale is proposed by Alkermes (ALKS) officer David Joseph Gaffin. - Stock Titan | A 2,034-share sale is proposed by Alkermes (ALKS) officer David Joseph Gaffin. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth | The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bullish | 1 | 1 |
| Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth | The global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bullish | 1 | 1 |
| LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now? - Zacks Investment Research | LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now? Zacks Investment Research | View source ↗ | Zacks Investment Research | Sep 30, 2026 | neutral | 0 | 0.6 |
| Alkermes (ALKS) Stock Looks Rich As Fresh ADHD Trial News Lands - Simply Wall Street | Alkermes (ALKS) Stock Looks Rich As Fresh ADHD Trial News Lands Simply Wall Street | View source ↗ | Simply Wall Street | Sep 29, 2026 | neutral | 0 | 0.6 |
| Alkermes: Idiopathic Hypersomnia Could Expand LUMRYZ Into A Larger Growth, Margin Driver - Seeking Alpha | Alkermes: Idiopathic Hypersomnia Could Expand LUMRYZ Into A Larger Growth, Margin Driver Seeking Alpha | View source ↗ | Seeking Alpha | Sep 26, 2026 | neutral | 0 | 0.6 |
| Alkermes (NasdaqGS:ALKS) Stock Forecast & Analyst Predictions - Simply Wall Street | Alkermes (NasdaqGS:ALKS) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 24, 2026 | neutral | 0 | 0.6 |
| What ALKS 7290 ADHD Trial Results Mean For Alkermes (ALKS) Stock - Simply Wall Street | What ALKS 7290 ADHD Trial Results Mean For Alkermes (ALKS) Stock Simply Wall Street | View source ↗ | Simply Wall Street | Sep 22, 2026 | neutral | 0 | 0.6 |
| An ADHD drug in testing cut symptom scores by 19 points - Stock Titan | An ADHD drug in testing cut symptom scores by 19 points Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| Alkermes (NASDAQ: ALKS) officer readies stock sale - Stock Titan | Alkermes (NASDAQ: ALKS) officer readies stock sale Stock Titan | View source ↗ | Stock Titan | Sep 3, 2026 | neutral | 0 | 0.6 |
| ALKS Stock Rises 27% in 3 Months: Here's What You Should Know - Yahoo Finance | ALKS Stock Rises 27% in 3 Months: Here's What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Aug 12, 2026 | neutral | 0 | 0.6 |
| Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure? - Yahoo Finance | Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 11, 2026 | neutral | 0 | 0.6 |
| Alkermes Stock 7-Day Winning Spree: Stock Climbs 25% - Trefis | Alkermes Stock 7-Day Winning Spree: Stock Climbs 25% Trefis | View source ↗ | Trefis | Jun 29, 2026 | neutral | 0 | 0.6 |
| 6-Day Rally Sends Alkermes Stock Up 20% - Trefis | 6-Day Rally Sends Alkermes Stock Up 20% Trefis | View source ↗ | Trefis | Jun 26, 2026 | neutral | 0 | 0.6 |
| ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits | ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes Stocktwits | View source ↗ | Stocktwits | Mar 31, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.